Introduction {#s1}
============

As the survival rate of breast cancer patients increases, optimal survivorship care has become an essential part of clinical practice ([@B1], [@B2]). One of the common long-term effects of breast cancer treatments is osteoporosis, with up to 80% of breast cancer patients experiencing bone loss ([@B3], [@B4]). Women with breast cancer, even in the absence of skeletal metastases, are known to have a higher incidence of fractures than women of the same age without breast cancer ([@B5]). Aromatase inhibitor (AI) is one of the well-known risk factors for osteoporosis in postmenopausal breast cancer patients ([@B6], [@B7]). Osteoporotic fractures impose an enormous health burden on individuals and take a substantial economic toll on society ([@B8]--[@B10]).

Tamoxifen is a known risk factor for osteoporosis in premenopausal breast cancer patients. In previous studies involving premenopausal breast cancer patients taking tamoxifen, bone mineral density decreased progressively over a 3-years follow-up period ([@B11]), and tamoxifen was associated with significant bone loss in patients who remained premenopausal after adjuvant chemotherapy ([@B12]). Based on these studies, the American Cancer Society/American Society of Clinical Oncology (ACS/ASCO) guidelines recommend bone screening every 2 years for premenopausal women receiving tamoxifen ([@B13]).

However, these previous studies have limitations. The sample sizes were small and only univariate analyses were performed to calculate the difference between the tamoxifen and placebo groups. Also, the primary outcome was the percent change in bone mineral density (BMD) rather than clinically meaningful outcomes such as osteoporosis or osteoporotic fractures, and the follow-up periods were short. For these reasons, the effect of tamoxifen on osteoporosis risks in premenopausal breast cancer patients remains controversial. Therefore, we conducted this nationwide retrospective cohort study using data from the Health Insurance Review and Assessment Service (HIRA), which archives data from nearly 98% of all citizens in South Korea ([@B14]). The objective of this study was to investigate the incidence of and risk factors for osteoporosis and osteoporotic fractures in breast cancer patients and to assess whether tamoxifen is a risk factor for osteoporosis and osteoporotic fractures in younger breast cancer patients.

Materials and Methods {#s2}
=====================

Data Source
-----------

The HIRA, a governmental organization in South Korea, assesses healthcare services and makes reimbursement decisions under the national healthcare insurance service. The HIRA collects nationwide claims data from healthcare providers ([@B14]). The HIRA data consists of six parts: (1) general information; (2) healthcare services; (3) diagnoses; (4) outpatient prescriptions; (5) medication file; and (6) provider information. The diagnostic information is based on the International Classification of Diseases 10th revision (ICD-10).

Study Population
----------------

We selected the study period of January 2007 to December 2017 because of data availability. Newly diagnosed breast cancer was defined by the C50 code (invasive breast cancer) in combination with the specialized V193 claim code, which is an identifier for reimbursement of cancer patients ([@B15]). Because we considered a 2-years period before breast cancer diagnosis as a washout period to exclude prevalent breast cancer and any cancer, subjects were excluded from the study if they received a C code within that period. Patients who did not undergo breast cancer surgery and those with a history of *in situ* carcinoma, presumed metastatic breast cancer, preexisting or recent (within 1 year after breast cancer diagnosis) osteoporosis, previous rheumatoid arthritis, or long-term corticosteroid treatment (more than 90 days) were excluded. Male patients or subjects who did not have follow-up claims data after breast cancer diagnosis were also excluded.

From January 2009 to December 2014, a total of 191,942 patients received C50 and V193 codes in the HIRA database. We excluded 118,820 who had *C* codes (any cancer) within the washout period. We excluded 2,531 patients with a previous history of *in situ* carcinoma, 5,801 with metastatic or recurrent breast cancer, 8,433 with preexisting or recently diagnosed osteoporosis, 134 with previous rheumatoid arthritis, 2,046 with long-term corticosteroid treatment, and 6,336 who did not undergo breast cancer surgery. One hundred eighty-seven male patients and 4 patients who did not have follow-up data after breast cancer diagnosis were also excluded ([Figure 1](#F1){ref-type="fig"}).

![Study population.](fonc-10-00366-g0001){#F1}

Variables and Operational Definitions
-------------------------------------

Patients\' characteristics such as age, type of insurance (health insurance vs. medical aid), and the Charlson Comorbidity Index (CCI) based on ICD-10 codes were analyzed ([@B16]). We defined the treatment groups based on claims data within 1 year after breast cancer diagnosis. Radiation therapy (either left and/or right), chemotherapy, ovarian function suppression (OFS), trastuzumab, and endocrine treatment (tamoxifen or AI) were reviewed. Regardless of whether they may have subsequently switched anti-hormonal medications, the patients were allocated into treatment groups according to the initially prescribed endocrine therapy. We defined osteoporosis as the newly claimed osteoporosis codes (M80, M81, M82) in conjunction with at least one of osteoporosis medications (pamidronate, alendronate, ibandronate, risedronate, tibolone, dienogest, estradiol hemihydrate, estradiol valerate, estropipate, conjugated equine estrogens, medroxyprogesterone acetate). The development of osteoporosis was defined using the newly claimed diagnosis in conjunction with medications. Osteoporotic fracture was defined as fracture-related codes (M80, osteoporosis with pathological fracture; S22, fracture of rib, sternum, and thoracic spine; S32, fracture of lumbar spine and pelvis; S52, fracture of forearm; S62, fracture at wrist and hand; S72, fracture of femur) or treatment of fractures and osteoporosis within 6 months before or after the fracture.

Statistical Analysis
--------------------

The baseline characteristics of the included patients are presented as the number of patients (%) or mean ± SD. The incidence rates of osteoporosis and osteoporotic fracture were calculated by dividing the number of incident cases by the total follow-up period (person-years). The disease-free probability of osteoporosis and osteoporotic fracture were calculated by the Kaplan-Meier method, and the log-rank test was performed to confirm differences across risk factors.

For the identification of risk factors for osteoporosis and osteoporotic fracture, a multivariable Cox proportional hazard regression model was applied and adjusted hazard ratio (HR) and 95% confidence interval (CI) were estimated. Age, type of insurance, CCI, chemotherapy, endocrine therapy, OFS, radiotherapy, and trastuzumab were selected as covariates for regression models. Subgroup analyses were performed within age groups (\<40, 40--49, 50--59, 60--69, and ≥70 years) to further clarify risk factors of osteoporosis and osteoporotic fracture.

Statistical analyses were performed with SAS software (version 9.4, SAS Institute, Cary, NC, USA). This study was approved by the Soonchunhyang University Seoul Hospital Institutional Review Board (IRB no. SCHUH 2018-11-011).

Results {#s3}
=======

Baseline Characteristics
------------------------

A total of 47,649 breast cancer survivors were included in this analysis. Among them, the proportion aged 40--49 years at the time of diagnosis was 42.04 % ([Table 1](#T1){ref-type="table"}). The proportion of breast cancer survivors who received any type of chemotherapy was 67.57% (*n* = 32,198). More than two-thirds of the survivors received endocrine treatment, and tamoxifen was the most frequently prescribed agent. OFS with goserelin or leuprolide was prescribed in 10.54% of the survivors. All the subjects underwent breast cancer surgeries, according to our operational definition.

###### 

Baseline characteristics and adjuvant treatments in breast cancer survivors.

                                                                          **Number (%)**
  ----------------------------------------------------------------------- ----------------
  **Total**                                                               47,649
  **Age at diagnosis[^\*^](#TN1){ref-type="table-fn"}**                   48.92 ± 9.82
  \<30                                                                    657 (1.38)
  30--39                                                                  6,464 (13.57)
  40--49                                                                  20,034 (42.04)
  50--59                                                                  13,968 (29.31)
  60--69                                                                  4,808 (10.09)
  70--79                                                                  1,510 (3.17)
  80-                                                                     208 (0.44)
  **Charlson comorbidity index[^\*^](#TN1){ref-type="table-fn"}**         1.34 ± 1.42
  0                                                                       15,579 (32.70)
  1                                                                       15,081 (31.65)
  2                                                                       9,120 (19.14)
  3                                                                       4,179 (8.77)
  4                                                                       1,891 (3.97)
  ≥5                                                                      1,799 (3.76)
  **Reimbursement type**                                                  
  National health insurance                                               46,871 (98.37)
  Medical aid                                                             777 (1.63)
  Others                                                                  1 (0.00)
  **Chemotherapy(any)**                                                   
  No                                                                      15,451 (32.43)
  Yes                                                                     32,198 (67.57)
  **Endocrine treatment**                                                 
  No                                                                      13,312 (27.94)
  Tamoxifen                                                               24,006 (50.38)
  Aromatase inhibitor[^\*\*^](#TN2){ref-type="table-fn"}                  10,331 (21.68)
  **Ovarian function suppression[^\*\*\*^](#TN3){ref-type="table-fn"}**   
  No                                                                      42,627 (89.46)
  Yes                                                                     5,022 (10.54)
  **Radiotherapy**                                                        
  No                                                                      13,301 (27.91)
  Yes                                                                     34,348 (72.09)
  **Trastuzumab**                                                         
  No                                                                      40,930 (85.90)
  Yes                                                                     6,719 (14.10)

presented as Mean ± SD, measured at breast cancer diagnosis.

letrozole, anastrozole, exemestane.

*goserelin, leuprolide*.

Incidence of Osteoporosis and Osteoporotic Fracture
---------------------------------------------------

During the study period, 5,955 osteoporosis events were observed in 252,396 person-years. The incidence rate of osteoporosis in breast cancer survivors was 23.59 per 1000 person-years (95% CI, 23.00--24.20). Osteoporotic fracture incidence was assessed as 2.40 per 1000 person-years (95% CI, 2.23--2.60), with 647 events occurring in 269,075 person-years ([Table 2](#T2){ref-type="table"}). Age at diagnosis and CCI were significantly associated with development of osteoporosis (*p* \< 0.0001) and osteoporotic fracture (*p* \< 0.0001) in the univariate analysis. The incidence rate of osteoporosis was highest in patients aged 70--79 years. The risk of osteoporotic fracture was highest in patients older than 80 years (17.16 per 1,000 person-years) followed by patients aged 70--79 years. Event-free probability of osteoporosis and osteoporotic fracture after 1 year following breast cancer diagnosis is presented in [Supplementary Figure 1](#SM1){ref-type="supplementary-material"}.

###### 

Incidence rates of osteoporosis and osteoporotic fracture according to age at diagnosis and comorbidities.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                               **N**    **Events**\   **Total person-year**   **Incidence rate**\           **HR**\                 ***p*[^\*^](#TN4){ref-type="table-fn"}**
                                                        **(*n*)**                             **(per 1,000 person-year)**   **(95% CI)**            
  -------------------------------------------- -------- ------------- ----------------------- ----------------------------- ----------------------- ------------------------------------------
  **Osteoporosis**                                                                                                                                  

  **Total**                                    47,649   5,955         2,52,396                23.59 (23.00--24.20)                                  

  **Age at diagnosis**                                                                                                      \<0.0001                

  \<30                                         657      6             3,771                   1.59 (0.71--3.54)             1 (Ref)                 

  30--39                                       6,464    161           37,017                  4.35 (3.73--5.08)             2.73 (1.21--6.16)       

  40--49                                       20,034   1521          1,10,010                13.83 (13.15--14.54)          8.67 (3.89--19.34)      

  50--59                                       13,968   2,409         71,240                  33.82 (32.49--35.19)          21.33 (9.57--47.52)     

  60--69                                       4,808    1,360         22,766                  59.74 (56.65--63.00)          37.97 (17.03--84.65)    

  70--79                                       1,510    455           6,773                   67.18 (61.28--73.64)          42.98 (19.21--96.18)    

  80+                                          208      43            819                     52.50 (38.94--70.79)          33.82 (14.39--79.45)    

  **CCI[^\*\*^](#TN5){ref-type="table-fn"}**                                                                                                        \<0.0001

  0                                            15,579   1,586         88,502                  17.92 (17.06--18.82)          1 (Ref)                 

  1                                            15,081   1,799         80,528                  22.34 (21.33--23.40)          1.24 (1.16--1.33)       

  2                                            9,120    1,225         45,839                  26.72 (25.27--28.26)          1.48 (1.38--1.60)       

  3                                            4,179    682           20,203                  33.76 (31.32--36.39)          1.88 (1.72--2.05)       

  4                                            1,891    334           9,079                   36.79 (33.05--40.95)          2.05 (1.82--2.30)       

  ≥5                                           1,799    329           8,245                   39.90 (35.81--44.45)          2.22 (1.97--2.50)       

  **Osteoporotic fracture**                                                                                                                         

  **Total**                                    47,649   647           2,69,075                2.40 (2.23--2.60)                                     \<0.0001

  **Age at diagnosis**                                                                                                                              

  \<40                                         7,121    9             41,247                  0.22 (0.11--0.42)             1 (Ref)                 

  40--49                                       20,034   110           1,14,136                0.96 (0.80--1.16)             4.45 (2.25--8.77)       

  50--59                                       13,968   221           78,053                  2.83 (2.48--3.23)             13.15 (6.75--25.61)     

  60--69                                       4,808    180           26,762                  6.73 (5.81--7.78)             31.20 (15.97--60.94)    

  70--79                                       1,510    111           7,944                   13.97 (11.60--16.83)          65.87 (33.40--129.94)   

  80+                                          208      16            933                     17.16 (10.51--28.00)          85.30 (37.69--193.08)   

  **CCI[^\*\*^](#TN5){ref-type="table-fn"}**                                                                                                        \<0.0001

  0                                            15,579   156           93,225                  1.67 (1.43--1.96)             1 (Ref)                 

  1                                            15,081   178           85,669                  2.08 (1.79--2.41)             1.27 (1.03--1.58)       

  2                                            9,120    129           49,196                  2.62 (2.21--3.12)             1.64 (1.30--2.08)       

  3                                            4,179    83            22,033                  3.77 (3.04--4.67)             2.38 (1.82--3.11)       

  4                                            1,891    50            9,918                   5.04 (3.82--6.65)             3.19 (2.32--4.39)       

  ≥5                                           1,799    51            9,034                   5.65 (4.29--7.43)             3.63 (2.64--4.98)       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

p-value from log-rank test.

*CCI, Charlson Comorbidity Index*.

Risk Factors for Osteoporosis and Osteoporotic Fracture According to Age at Diagnosis
-------------------------------------------------------------------------------------

Factors associated with the incidence of osteoporosis and osteoporotic fracture showed different patterns according to age subgroups ([Table 3](#T3){ref-type="table"}). In patients younger than 40 years, the use of OFS was significantly related to an increased incidence of osteoporosis. In the age 40--49 group, chemotherapy, AI and OFS were significantly associated with an increased risk of osteoporosis. In patients aged 50--69 years, AI significantly increased the risk of osteoporosis; in contrast, tamoxifen was associated with a decreased risk of osteoporosis.

###### 

Factors associated with osteoporosis according to age subgroups in univariate and multivariate analysis.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                          **N**    **Events (*n*)**   **Total person-year**   **Incidence rate**\           ***p*[^\*^](#TN6){ref-type="table-fn"}**   **Crude HR**\        **Adjusted HR**\
                                                                                                                              **(per 1,000 person-year)**                                              **(95% CI)**         **(95% CI)**
  ----------------------------------------------------------------------- -------- ------------------ ----------------------- ----------------------------- ------------------------------------------ -------------------- --------------------
  **Age \<40**                                                                                                                                                                                                              

  **Reimbursement type**                                                                                                                                    0.1178                                                          

  National health insurance                                               7,068    164                40,477                  4.05 (3.48--4.72)                                                        1 (Ref)              1 (Ref)

  Medical aid                                                             53       3                  311                     9.66 (3.11--29.94)                                                       2.42 (0.77--7.57)    2.49 (0.85--7.25)

  **Chemotherapy(any)**                                                                                                                                     0.5516                                                          

  No                                                                      1,878    41                 10,837                  3.78 (2.79--5.14)                                                        1 (Ref)              1 (Ref)

  Yes                                                                     5,243    126                29,951                  4.21 (3.53--5.01)                                                        1.11 (0.78--1.58)    1.39 (0.95--2.02)

  **Endocrine treatment**                                                                                                                                   0.0363                                                          

  No                                                                      2,364    40                 13,446                  2.97 (2.18--4.06)                                                        1 (Ref)              1 (Ref)

  Tamoxifen                                                               4,736    127                27,220                  4.67 (3.92--5.55)                                                        1.55 (1.08--2.21)    1.24 (0.85--1.82)

  Aromatase inhibitor[^\*\*^](#TN7){ref-type="table-fn"}                  21       0                  121                     0.00                                                                     1.34 (0.08--22.02)   1.33 (0.08--22.34)

  **Ovarian function suppression[^\*\*\*^](#TN8){ref-type="table-fn"}**                                                       \<0.0001                                                                                      

  No                                                                      5,632    108                32,433                  3.33 (2.76--4.02)                                                        1 (Ref)              1 (Ref)

  Yes                                                                     1,489    59                 8,355                   7.06 (5.47--9.11)                                                        2.12 (1.54--2.91)    2.15 (1.52--3.06)

  **Radiotherapy**                                                                                                                                          0.859                                                           

  No                                                                      1,864    45                 10,761                  4.18 (3.12--5.60)                                                        1 (Ref)              1 (Ref)

  Yes                                                                     5,257    122                30,027                  4.06 (3.40--4.85)                                                        0.97 (0.69--1.36)    0.92 (0.65--1.30)

  **Trastuzumab**                                                                                                                                           0.8198                                                          

  No                                                                      6,119    146                35,440                  4.12 (3.50--4.85)                                                        1 (Ref)              1 (Ref)

  Yes                                                                     1,002    21                 5,348                   3.93 (2.56--6.02)                                                        0.95 (0.60--1.50)    0.99 (0.62--1.59)

  **Age 40--49**                                                                                                                                                                                                            

  **Reimbursement type**                                                                                                                                    0.7624                                                          

  National health insurance                                               19,729   1,499              1,08,318                13.84 (13.16--14.56)                                                     1 (Ref)              1 (Ref)

  Medical aid                                                             305      22                 1,693                   13.00 (8.56--19.74)                                                      0.94 (0.62--1.43)    0.81 (0.53--1.24)

  **Chemotherapy(any)**                                                                                                                                     \<0.0001                                                        

  No                                                                      6,424    381                35,732                  10.66 (9.64--11.79)                                                      1 (Ref)              1 (Ref)

  Yes                                                                     13,610   1,140              74,278                  15.35 (14.48--16.27)                                                     1.45 (1.29--1.62)    1.41 (1.24--1.60)

  **Endocrine treatment**                                                                                                                                   \<0.0001                                                        

  No                                                                      4,448    383                23,888                  16.03 (14.51--17.72)                                                     1 (Ref)              1 (Ref)

  Tamoxifen                                                               14,710   950                81,377                  11.67 (10.95--12.44)                                                     0.72 (0.64--0.82)    0.74 (0.65--0.84)

  Aromatase inhibitor[^\*\*^](#TN7){ref-type="table-fn"}                  876      188                4,745                   39.62 (34.34--45.71)                                                     2.47 (2.08--2.94)    2.45 (2.05--2.92)

  **Ovarian function suppression[^\*\*\*^](#TN8){ref-type="table-fn"}**                                                       0.0113                                                                                        

  No                                                                      16,838   1,314              92,422                  14.22 (13.47--15.01)                                                     1 (Ref)              1 (Ref)

  Yes                                                                     3,196    207                17,588                  11.77 (10.27--13.49)                                                     0.83 (0.71--0.96)    1.19 (1.01--1.40)

  **Radiotherapy**                                                                                                                                          0.0548                                                          

  No                                                                      5,130    427                28,435                  15.02 (13.66--16.51)                                                     1 (Ref)              1 (Ref)

  Yes                                                                     14,904   1,094              81,575                  13.41 (12.64--14.23)                                                     0.90 (0.80--1.00)    0.87 (0.77--0.97)

  **Trastuzumab**                                                                                                                                           0.0282                                                          

  No                                                                      17,546   1,320              97,261                  13.57 (12.86--14.32)                                                     1 (Ref)              1 (Ref)

  Yes                                                                     2,488    201                12,749                  15.77 (13.73--18.10)                                                     1.18 (1.02--1.37)    1.04 (0.89--1.21)

  **Age 50--59**                                                                                                                                                                                                            

  **Reimbursement type**                                                                                                                                    0.9962                                                          

  National health insurance                                               13,763   2,374              70,202                  33.82 (32.48--35.20)                                                     1 (Ref)              1 (Ref)

  Medical aid                                                             205      35                 1,038                   33.73 (24.22--46.98)                                                     1.00 (0.72--1.40)    1.01 (0.72--1.41)

  **Chemotherapy(any)**                                                                                                                                     \<0.0001                                                        

  No                                                                      4,166    643                21,789                  29.51 (27.32--31.88)                                                     1 (Ref)              1 (Ref)

  Yes                                                                     9,802    1,766              49,452                  35.71 (34.08--37.42)                                                     1.21 (1.11--1.33)    1.09 (0.99--1.20)

  **Endocrine treatment**                                                                                                                                   \<0.0001                                                        

  No                                                                      4,526    752                22,869                  32.88 (30.61--35.32)                                                     1 (Ref)              1 (Ref)

  Tamoxifen                                                               3,555    405                19,237                  21.05 (19.10--23.21)                                                     0.64 (0.56--0.72)    0.69 (0.61--0.78)

  Aromatase inhibitor[^\*\*^](#TN7){ref-type="table-fn"}                  5,887    1,252              29,134                  42.97 (40.66--45.42)                                                     1.31 (1.19--1.43)    1.34 (1.22--1.47)

  **Ovarian function suppression[^\*\*\*^](#TN8){ref-type="table-fn"}**                                                       \<0.0001                                                                                      

  No                                                                      13,631   2,385              69,368                  34.38 (33.03--35.79)                                                     1 (Ref)              1 (Ref)

  Yes                                                                     337      24                 1,872                   12.82 (8.59--19.13)                                                      0.37 (0.25--0.56)    0.61 (0.40--0.92)

  **Radiotherapy**                                                                                                                                          0.8216                                                          

  No                                                                      3,732    657                19,327                  33.99 (31.49--36.69)                                                     1 (Ref)              1 (Ref)

  Yes                                                                     10,236   1,752              51,913                  33.75 (32.21--35.37)                                                     0.99 (0.90--1.08)    0.94 (0.86--1.03)

  **Trastuzumab**                                                                                                                                           0.0158                                                          

  No                                                                      11,535   1,970              59,582                  33.06 (31.64--34.56)                                                     1 (Ref)              1 (Ref)

  Yes                                                                     2,433    439                11,658                  37.66 (34.29--41.35)                                                     1.14 (1.02--1.26)    1.09 (0.98--1.22)

  **Age 60--69**                                                                                                                                                                                                            

  **Reimbursement type**                                                                                                                                    0.0231                                                          

  National health insurance                                               4,673    1,311              22,166                  59.15 (56.03--62.44)                                                     1 (Ref)              1 (Ref)

  Medical aid                                                             135      49                 600                     81.65 (61.71--108.03)                                                    1.39 (1.05--1.85)    1.42 (1.06--1.89)

  **Chemotherapy(any)**                                                                                                                                     0.0450                                                          

  No                                                                      1,778    483                8,679                   55.65 (50.91--60.85)                                                     1 (Ref)              1 (Ref)

  Yes                                                                     3,030    877                14,087                  62.25 (58.27--66.51)                                                     1.12 (1.00--1.25)    1.11 (0.99--1.25)

  **Endocrine treatment**                                                                                                                                   \<0.0001                                                        

  No                                                                      1,463    389                6,818                   57.05 (51.66--63.01)                                                     1 (Ref)              1 (Ref)

  Tamoxifen                                                               651      151                3,357                   44.98 (38.35--52.76)                                                     0.79 (0.65--0.95)    0.81 (0.67--0.99)

  Aromatase inhibitor[^\*\*^](#TN7){ref-type="table-fn"}                  2,694    820                12,591                  65.13 (60.82--69.74)                                                     1.14 (1.01--1.28)    1.18 (1.04--1.34)

  **Ovarian function suppression[^\*\*\*^](#TN8){ref-type="table-fn"}**                                                       NA                                                                                            

  No                                                                      4,808    1,360              22,766                  59.74 (56.65--63.00)          NA                                         NA                   NA

  Yes                                                                     0        NA                 NA                      NA                            NA                                         NA                   NA

  **Radiotherapy**                                                                                                                                          0.3174                                                          

  No                                                                      1,584    469                7,597                   61.73 (56.39--67.58)                                                     1 (Ref)              1 (Ref)

  Yes                                                                     3,224    891                15,168                  58.74 (55.01--62.73)                                                     0.94 (0.84--1.06)    0.92 (0.83--1.04)

  **Trastuzumab**                                                                                                                                           0.7159                                                          

  No                                                                      4,121    1,170              19,683                  59.44 (56.13--62.95)                                                     1 (Ref)              1 (Ref)

  Yes                                                                     687      190                3,082                   61.64 (53.47--71.06)                                                     1.03 (0.88--1.20)    1.01 (0.86--1.19)

  **Age** **≥70**                                                                                                                                                                                                           

  **Reimbursement type**                                                                                                                                    0.665                                                           

  National health insurance                                               1,638    476                7,225                   65.88 (60.22--72.08)                                                     1 (Ref)              1 (Ref)

  Medical aid                                                             80       22                 367                     59.90 (39.44--90.96)                                                     0.91 (0.59--1.40)    0.91 (0.59--1.39)

  **Chemotherapy(any)**                                                                                                                                     0.0289                                                          

  No                                                                      1,205    333                5,416                   61.49 (55.22--68.46)                                                     1 (Ref)              1 (Ref)

  Yes                                                                     513      165                2,176                   75.81 (65.08--88.31)                                                     1.23 (1.02--1.48)    1.18 (0.96--1.45)

  **Endocrine treatment**                                                                                                                                   0.0126                                                          

  No                                                                      511      139                2,132                   65.19 (55.21--76.98)                                                     1 (Ref)              1 (Ref)

  Tamoxifen                                                               354      86                 1,713                   50.22 (40.65--62.03)                                                     0.77 (0.59--1.01)    0.83 (0.63--1.10)

  Aromatase inhibitor[^\*\*^](#TN7){ref-type="table-fn"}                  853      273                3,747                   72.85 (64.70--82.02)                                                     1.11 (0.91--1.36)    1.19 (0.96--1.47)

  **Ovarian function suppression[^\*\*\*^](#TN8){ref-type="table-fn"}**                                                       NA                                                                                            

  No                                                                      1,718    498                7,592                   65.59 (60.08--71.61)          NA                                         NA                   NA

  Yes                                                                     0        NA                 NA                      NA                            NA                                         NA                   NA

  **Radiotherapy**                                                                                                                                          0.3657                                                          

  No                                                                      991      277                4,399                   62.97 (55.97--70.84)                                                     1 (Ref)              1 (Ref)

  Yes                                                                     727      221                3,193                   69.21 (60.66--78.97)                                                     1.09 (0.91--1.30)    1.05 (0.87--1.25)

  **Trastuzumab**                                                                                                                                           0.0760                                                          

  No                                                                      1,609    460                7,157                   64.27 (58.66--70.42)                                                     1 (Ref)              1 (Ref)

  Yes                                                                     109      38                 435                     87.33 (63.55--120.02)                                                    1.35 (0.97--1.88)    1.22 (0.85--1.75)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA, not available.

log-rank test.

letrozole, anastrozole, exemestane.

*goserelin, leuprolide*.

There were only 9 cases of osteoporotic fracture in 7,121 patients younger than 40 years, and OFS was not associated with an increased risk of osteoporotic fracture in these patients ([Supplementary Table 1](#SM2){ref-type="supplementary-material"}). An increased risk of osteoporotic fracture was significantly associated with chemotherapy (HR, 1.75; 95% CI, 1.07--2.88) and AI (HR, 2.35; 95% CI, 1.34--4.12) in the age 40--49 subgroup.

Effect of Tamoxifen on Bone Health in Younger Breast Cancer Patients
--------------------------------------------------------------------

In the total population, tamoxifen was significantly associated with a decreased risk of osteoporosis and osteoporotic fracture ([Figure 2](#F2){ref-type="fig"}). The risk of osteoporosis (HR, 1.24; CI, 0.85--1.82) and osteoporotic fracture (HR, 8.15; CI, 0.36--186.70) was not associated with tamoxifen in patients younger than 40 years ([Table 3](#T3){ref-type="table"} and [Supplementary Table 1](#SM2){ref-type="supplementary-material"}). However, in the age 40--49 group, tamoxifen significantly decreased the risk of osteoporosis (HR, 0.74; CI, 0.65--0.84) and osteoporotic fracture (HR, 0.49; CI, 0.31--0.76).

![Kaplan-Meier event free probability according to endocrine treatment in total population (**A**: osteoporosis, **B**: osteoporotic fracture). Tam, tamoxifen; AI, aromatase inhibitor.](fonc-10-00366-g0002){#F2}

Discussion {#s4}
==========

The results of this large retrospective study show that the use of adjuvant tamoxifen does not increase the risk of osteoporosis and osteoporotic fracture in younger breast cancer survivors. In patients younger than 40 years at the time of breast cancer diagnosis, adjuvant tamoxifen was not associated with the development of osteoporosis and osteoporotic fracture. Furthermore, tamoxifen significantly decreased the risk of osteoporosis and osteoporotic fracture in breast cancer patients aged 40--49 years at the time of diagnosis. OFS was significantly associated with an increased risk of osteoporosis in patients younger than 50 years. Chemotherapy and AI were significantly related to the risk of osteoporosis and osteoporotic fracture in patients between the ages of 40 and 49 years.

The results of this study differ from those of previous studies. Previous studies showed an association between tamoxifen use and bone loss in premenopausal patients. One previous study showed an annual loss of BMD of 1.44% in premenopausal breast cancer patients on tamoxifen ([@B11]). However, only 125 premenopausal breast cancer patients were enrolled in that study and treatment variables that can influence BMD were not statistically adjusted. Another study showed a 4.6% decrease in BMD at the 3-years follow-up evaluation in premenopausal patients taking tamoxifen after adjuvant chemotherapy. The number of patients enrolled in that study was also small, and only univariate analyses were conducted ([@B12]). Recently, researchers from Germany reported that tamoxifen increased the risk of fracture in premenopausal breast cancer patients compared to control patients without cancer ([@B17]). However, the selection criteria for the non-cancer control patients were not able to demonstrate the effect of tamoxifen on fracture because adjuvant treatments such as OFS and chemotherapy could not be statistically adjusted. To address these drawbacks, we conducted this nationwide retrospective cohort study.

To our knowledge, this is the largest retrospective cohort study of the effect of tamoxifen on bone health in younger breast cancer patients. Approximately 27,000 breast cancer patients younger than 50 years were enrolled, comprising 150,798 person-years. The results of this study indicate that tamoxifen does not increase the risk of osteoporosis and osteoporotic fracture in younger breast cancer survivors. These results contradict the ASCO recommendation that primary clinicians should refer premenopausal breast cancer survivors who are taking tamoxifen for repeat bone screening every 2 years ([@B13]).

One of the interesting findings of this study is that tamoxifen significantly decreased the risk of osteoporosis and osteoporotic fracture in breast cancer patients aged 40 to 49 years at the time of diagnosis. This can be explained by their perimenopausal status and long-term treatment with adjuvant tamoxifen. For patients with hormone receptor-positive breast cancers and lymph node metastasis, 10 years of adjuvant tamoxifen treatment are usually recommended ([@B18]). With the extended tamoxifen therapy, premenopausal women who are premenopausal at the time of breast cancer diagnosis might continue to take tamoxifen beyond the start of menopause, after which tamoxifen would show a protective effect on bone health.

In postmenopausal patients, AI increases the incidence of osteoporosis and osteoporotic fracture. The current study, in accordance with other reports ([@B19], [@B20]), demonstrated a marked increase in the risk of osteoporosis with AI, reflecting the near-complete estrogen depletion and subsequent disruption in bone homeostasis caused by these agents ([@B21]).

Multiple factors are related to the incidence of osteoporosis. The most common causes of bone loss in women are menopause and aging. Aging is associated with greater bone resorption and less bone formation, whereas menopause induces accelerated bone loss due to lowering levels of endogenous estrogen ([@B22]). In HIRA data study about the burden of osteoporosis in the general population, the prevalence of osteoporosis increased with age; the peak was at 70--79 years, with a rate of 5,253 diagnoses per 10,000 persons ([@B23]). Although we cannot directly compare this to the results of our study because of the different operational definitions, we similarly found an increasing incidence of osteoporosis in the older age group.

The limitations of this study should be noted. First, we were not able to perform survival analysis because the HIRA data is claims-based in accordance with the Personal Information Protection Act in Korea. Therefore, we could not assess the effect of osteoporosis and osteoporotic fracture on overall survival. Second, endocrine therapy treatment group allocation was based on claims data from the 1st year after diagnosis, and some patients may have subsequently switched from tamoxifen to AI. Third, as we defined osteoporosis as osteoporosis diagnosis codes in combination with osteoporosis medications, osteoporosis patients to whom osteoporosis medications were not prescribed due to other medical conditions were not included in this analysis. Lastly, due to the limitations of claims data, we were unable to gather information about diet, exercise, exposure to sunlight, and vitamin D supplementation, which are important factors for maintaining bone health.

The results of this study should be interpreted in the context of the study period. First, we did not analyze the use of denosumab which has been reimbursed for osteoporosis treatment from 2018 in South Korea. The resulting change in clinical practice could potentially affect the study outcomes. Second, after the practice-changing report from the Suppression of Ovarian Function Trial in 2015, adjuvant ovarian suppression in premenopausal breast cancer patients who remain premenopausal after chemotherapy, especially young patients, is recommended ([@B24]). Although OFS was not associated with a significantly increased risk of osteoporotic fracture in patients younger than 40 years in this study, OFS is now more often prescribed, possibly affecting the incidence of osteoporosis and osteoporotic fractures.

In conclusion, tamoxifen is not associated with an increased risk of osteoporosis and osteoporotic fracture in premenopausal breast cancer patients. Risk factors for osteoporosis and osteoporotic fractures vary according to patient age. Tailored screening strategies for breast cancer survivors who are at different risks of developing osteoporosis are needed.
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